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http://dx.doi.org/10.1016/j.ccr.2012.09.004SUMMARYRhabdomyosarcoma (RMS) is an aggressive skeletal muscle-lineage tumor composed of malignant
myoblasts that fail to exit the cell cycle and are blocked from fusing into syncytial muscle. Rhabdomyosar-
coma includes two histolopathologic subtypes: alveolar rhabdomyosarcoma, driven by the fusion protein
PAX3-FOXO1 or PAX7-FOXO1, and embryonal rhabdomyosarcoma (ERMS), which is genetically heteroge-
neous. Here, we show that adipocyte-restricted activation of Sonic hedgehog signaling through expression
of a constitutively active Smoothened allele in mice gives rise to aggressive skeletal muscle tumors that
display the histologic and molecular characteristics of human ERMS with high penetrance. Our findings
suggest that adipocyte progenitors can be a cell of origin for Sonic hedgehog-driven ERMS, showing that
RMS can originate from nonskeletal muscle precursors.INTRODUCTION
Rhabdomyosarcoma (RMS) is an aggressive skeletal muscle-
lineage malignancy and the most common soft tissue sarcoma
in children (Barr andWomer, 2009). RMS is comprised of skeletal
muscle precursors that fail to exit the cell cycle and are irrevers-
ibly blocked from differentiating into syncytial muscle. RMS is
typically divided into two histopathologic subgroups, each with
distinct clinical features: embryonal RMS (ERMS), which is the
more common subtype, and alveolar RMS (ARMS), which is
notoriously more aggressive. The genetic lesions that initiate
ARMS are well known with three-quarters of ARMS tumors
having chromosomal translocations that result in expressing
fusion proteins combining the DNA binding domain of either
PAX3 or PAX7 transcription factors with the transcriptional acti-Significance
Rhabdomyosarcoma is the most common soft tissue malign
therapy, and surgery, clinical outcomes for RMS have not imp
themolecular underpinnings of the disease. Here, we describe
the histopathological and molecular characteristics of human E
and a restricted anatomic location when compared to previo
ERMS, this mouse model also now provides a robust preclin
RMS treatment.
536 Cancer Cell 22, 536–546, October 16, 2012 ª2012 Elsevier Inc.vation domain of FOXO1A (Barr, 2001). Because PAX3 and PAX7
have critical roles in normal muscle development, the fusion
proteins presumably use the DNA binding domains of the PAX
proteins to drive malignant myogensis-related developmental
programs (Galindo et al., 2006; Keller and Capecchi, 2005;
Wang et al., 2008). ERMS accounts for 75% of RMS cases and
is associated with younger age of onset (typically under ten
years) and demonstrates a predilection for tissues of the head
and neck. The molecular underpinnings and cellular origins of
ERMS remain poorly understood. Although most cases of
ERMS occur as sporadic, nonheritable tumors, ERMS also
associates with familial syndromes caused by mutations in
prominent oncogenesis-related signaling pathways, such as
p53, Ras, and Sonic hedgehog (Shh) (Estep et al., 2006; Johnson
et al., 1996; Li and Fraumeni, 1969).ancy in children. Despite aggressive chemotherapy, radio-
roved for three decades, emphasizing the need to uncover
a Sonic hedgehog-drivenmousemodel of ERMS that mimics
RMS, and with notably decreased latency, high penetrance,
us models. In addition to yielding mechanistic insights into
ical platform to explore therapeutic strategies to improve
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Figure 1. ERMS Caused by Activation of the Sonic Hedgehog Pathway in the aP2 Lineage
(A) Schematic of the conditional SmoM2 allele and aP2-Cre-mediated recombination.
(B) Gross view of tumors in aP2-Cre;SmoM2 mice.
(C) Kaplan-Meier survival curves illustrated tumor-free survival of aP2-Cre;SmoM2/+ mice (blue line, n = 47) compared to SmoM2/+ littermate controls (red line,
n = 19) (p = < 0.0001).
(D) Cross-sectional histology of tumors with H&E staining. Arrow points to rhabdomyoblast and arrowhead points to strap cell.
(E) Masson’s trichrome.
(F–I) Sections of tumors immunostained with Ki67, a marker of proliferating cells (F), and Desmin (G), MyoD1 (H), andMyogenin (I), diagnostic of ERMS. Scale bar,
50 mm (D, E, and G–I) and 200 mm (F).
See also Figure S1.
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Adipocyte Origin of RhabdomyosarcomaThe Shh pathway is an evolutionarily conserved signaling
pathway with noted roles in development and in tumorigenesis.
Normally, in the absence of extracellular Shh ligand, the Shh
signaling pathway is inhibited by the Patched (Ptch) transmem-
brane receptor, which dominantly represses the Smoothened
(Smo) G protein coupled receptor. Upon binding of Shh to
Ptch, Smo is freed from Ptch-mediated inhibition and activates
the Gli family of transcription factors (Gli1, Gli2, and Gli3) that
then drive patterns of gene expression critical for various
aspects of development (Lum and Beachy, 2004). Shh-associ-
ated diseases include nevoid basal cell carcinoma syndrome
(Gorlin syndrome), an autosomal dominant condition caused
by heterozygous germ-line mutations in PTCH1, which drives
basal cell carcinoma, medulloblastoma, and ERMS. Activation
of the Shh pathway is also found in spontaneous ERMS tumors,
associating with either loss of Shh pathway negative regulators,
such as PTCH1 or PTCH2 or Suppressor of Fused (SUFU), or
by the activation of the downstream transcriptional effector of
Shh signaling, Gli (Paulson et al., 2011; Tostar et al., 2006).
Consistent with human ERMS, introducing Shh-pathway-
activating mutations in mouse models induces tumorigenesis.
Transgenic mice with heterozygous deletion of Ptch1 develop
tumors histologically consistent with ERMS but with a low level
of penetrance (10%) (Corcoran and Scott, 2001; Hahn et al.,
2000). Mice with heterozygous loss of Sufu in combination with
p53 loss develop ERMS with 9% penetrance (Lee et al., 2007).
The most robust mouse model of ERMS utilizes a conditional,Cconstitutively activate Smo allele (SmoM2) controlled by a ubiqui-
tously expressed, inducible Cre transgene,CAGGS-CreER (Mao
et al., 2006). Although these models point to the involvement of
the Shh pathway in the pathogenesis of ERMS, the varied
anatomic location, relatively low penetrance of tumorigenesis
and occurrence of other tumor types in these models limit their
usefulness as a preclinical platform. We have generated a trans-
genic mouse model in which overexpression of the oncogenic
SmoM2 allele in the adipocyte-restricted aP2 lineage induces
tumors that closely resemble human ERMS.
RESULTS
SmoM2 Expression in the aP2 Lineage Causes ERMS
We initially sought to explore the role of Shh signaling in adipo-
cyte development and metabolism, using an adipose protein
2 (aP2)-Cre transgenic driver (Tang et al., 2008) to conditionally
express constitutively activated Smoothened, SmoM2 (Mao
et al., 2006) in an adipocytic-specific pattern (Figure 1A). Sur-
prisingly, 80% of mice with the genotype aP2-Cre;SmoM2/+
developed large, aggressive tumors in the head and ventral
neck by 2months of age (Figures 1B and 1C). The tumors ranged
in greatest diameter from 1 to 2 cm, were tan/pink/white and
solid upon sectioning, and well demarcated from the surround-
ing nonneoplastic tissue. Histologic examination revealed
ERMS-type morphology: the tumors displayed dense cellularity,
comprised of a spectrum of cells that were small and roundancer Cell 22, 536–546, October 16, 2012 ª2012 Elsevier Inc. 537
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Figure 2. Sonic Hedgehog Activation in aP2-Cre;SmoM2 Tumors
(A) b-galactosidase enzymatic staining of cross sections of aP2-Cre;
SmoM2;R26-LacZ reporter mouse tumors and aP2-Cre;SmoM2 tumors illus-
trating broad homogeneous staining. Scale bar, 5 mm.
(B) Increased expression on Sonic hedgehog pathway target genes in the
aP2-Cre;SmoM2/+ tumors compared to mature SCM of aP2-Cre;SmoM2/+ and
SmoM2/+ animals by real-time PCR. Data are shown as fold change of gene
expression normalized to 18S and expressed relative to SCM of SmoM2/+.
Results are mean ± SEM (n = 4). p values by two-tailed, unpaired Student’s
t test are as follows: Smo (p = 0.0015), Gli1 (p < 0.0001), Gli3 (p < 0.0001), and
Ptch1 (p < 0.0001).
(C and D) Expression of embryonic muscle development genes (C) and
markers of terminally differentiated skeletal muscle (D) in aP2-Cre;SmoM2/+
tumors compared to mature SCM as detected by real-time PCR. Data
are shown as fold change of gene expression normalized to 18S and ex-
pressed relative to SCM of SmoM2/+. Results are mean ± SEM (n = 3). p values
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538 Cancer Cell 22, 536–546, October 16, 2012 ª2012 Elsevier Inc.to cells that were elongated and spindled, with brightly eosino-
philic cytoplasm, pleomorphic nuclei, and visible cross-striations
(Figures 1D and 1E). Immunohistochemistry (IHC) for Ki67
showed that the tumor cells were briskly mitotic (Figure 1F).
IHC also revealed strong expression of the muscle-specific
intermediate filament Desmin and nuclear staining for the
muscle-specific transcription factors Myogenin and MyoD1
(Figures 1G–1I). These findings are diagnostic for RMS.
Extensive analyses of the aP2 promoter in transgenic mice
have documented its specificity for the adipocyte lineage and
its exclusion from the skeletal muscle lineage (He et al., 2003;
Ross et al., 1990; Tang et al., 2008; Urs et al., 2006). Thus, it
was surprising to observe RMS tumorigenesis in aP2-Cre;
SmoM2 mice. To test whether aP2-Cre activation of the SmoM2
allele altered or interfered with normal skeletal muscle and/or
adipose development, we performed histologic analysis of
the sternocleidomastoid (SCM), quadriceps femoris, intra-
scapular brown fat, and inguinal white fat from 4- to 8-week-
old aP2-Cre;SmoM2/+ and SmoM2/+ control mice. We observed
no gross abnormalities in muscle or adipose tissue in either
cohort (Figure S1 available online). Therefore, activation of the
hedgehog pathway by aP2-Cre-mediated expression of the
SmoM2 allele did not evoke general defects in myogenesis or
adipogenesis.
Activation of Hedgehog Signaling
in aP2-Cre;SmoM2/+ Tumors
We analyzed in vivo the expression of the Cre-responsive
R26-LacZ reporter to confirm that the RMS tumors originate
from cell-autonomous activation of the SmoM2 allele. Intense,
homogenous b-galactosidase staining of the tumors revealed
that they formed as a consequence of cell-autonomous acti-
vation by aP2-Cre (Figure 2A). Next, to confirm that the Shh
pathway was activated in tumors of aP2-Cre;SmoM2/+ mice,
we compared the expression of Shh target genes in control
muscle and tumor tissue from both aP2-Cre;SmoM2/+ and
SmoM2/+ littermates. The tumors exhibited increased expression
of Smo and Shh responsive genes, including Gli1, Gli3, and
Ptch1 (Figure 2B), whereas gene expression in SCM muscle
was unchanged. These findings indicate that the Shh pathway
is robustly activated in the ERMS tumors but not in the nonneo-
plastic skeletal muscle of the aP2-Cre;SmoM2/+mice, suggesting
an origin of tumorigenesis distinct from skeletal muscle lineage
precursors.
aP2-Cre;SmoM2/+ Tumors Display an Embryonal
Muscle Gene Signature
To further determine the extent to which the aP2-Cre;SmoM2/+
tumors resembled ERMS, we isolated RNA from tumor tissue
and compared the gene expression profile to that of SCM skel-
etal muscle of SmoM2/+ littermates. Skeletal muscle regulatory
genes (MyoD1, Myogenin, Pax7, and Myf5) and embryonic/
perinatal myosins (Myh3 and Myh8) displayed markedly
increased expression in the aP2-Cre;SmoM2/+ tumors whenby two-tailed, unpaired Student’s t test are as follows: MyoD1 (p = 0.0011),
Myogenin (p = 0.0007), Pax7 (p = 0.0009),Myf5 (p = 0.0039),Myh3 (p = 0.0165),
Myh8 (p = 0.0007),Myh1 (p < 0.0001),Myh4 (p < 0.0001), andCkm (p < 0.0001).
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Figure 3. Comparative Transcriptome Anal-
ysis of Mouse ERMS and Skeletal Muscle
(A) Principle component analysis (PCA). Three
PCA coordinates describe 64.6% of the total data
variation (PC1, 52.9%; PC2, 5.99%; and PC3,
5.71%). Red, aP2-Cre;SmoM2/+ tumors (n = 12).
Green, SmoM2/+ SCM (n = 3).
(B) Volcano plot of the Log10 of the p value versus
the Log2 of the fold-difference in expression in
the aP2-Cre;SmoM2/+ tumors compared to the
normal skeletal muscle.
(C) Unsupervised hierarchical clustering analysis.
Each column represents a distinct sample, and
each row represents a distinct gene.
(D) Comparison of aP2-Cre;SmoM2 tumors to
published mouse ERMS models. Gene expressed
in both the published mouse ERMS models and
the aP2-Cre;SmoM2/+ tumors (19,878 genes)
plotted on graph. Sixty-seven percent of gene
pairs show agreement in genes upregulated (red)
or downregulated (green) between the previously
published mouse ERMS models and the aP2-
Cre;SmoM2 tumors. Spearman correlation = 0.59
and AGDEX = 0.71.
(E) Comparision of aP2-Cre;SmoM2/+ tumors to
human ERMS. Genes expressed in both the pub-
lished human ERMS and the aP2-Cre;SmoM2/+
tumors (13,282 genes) plotted on graph. Fifty-eight
percent of orthologous gene pairs show agree-
ment in genes upregulated (red) or downregulated
(green) between the human ERMS and the aP2-
Cre;SmoM2 tumors. Spearman correlation = 0.29
and AGDEX = 0.3.
See also Figure S2.
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Adipocyte Origin of Rhabdomyosarcomacompared to the SCM (Figure 2C). In contrast, markers of
mature, differentiated skeletal muscle (Myh1, Myh4, and Ckm)
were dramatically diminished in aP2-Cre;SmoM2/+ tumors
when compared to SCM (Figure 2D). This embryonal muscle
gene expression pattern is consistent with mouse and human
ERMS and is indicative of an arrested skeletal myoblastic tissue.
Gene Expression Profiling of aP2-Cre;SmoM2 Tumors
To further characterize the tumors of the aP2-Cre;SmoM2/+mice,
we used mRNA expression profiling to compare the gene
expression profiles of aP2-Cre;SmoM2/+ tumors and SCM. The
transcriptome of the aP2-Cre;SmoM2/+ tumors was distinct
from that of SCM using principle component analysis to group
samples based on gene expression (Figure 3A). Focusing on
changes of gene expression with a log2 ratio greater than 2.5
and a p value less that 0.0001 by Bonferroni, we identified 100
genes that were differentially expressed between aP2-Cre;
SmoM2/+ tumors and normal SCM of SmoM2/+ littermates
(Figures 3B and 3C). Consistent with the developing muscle
gene pattern, we noted that perinatal myosin heavy chain
Myh8 was among the genes expressed at high levels in the
tumors compared to normal SCM and mature myosin heavyCancer Cell 22, 536–546,chain Myh4 was among the genes that
exhibited low expression in the tumors
compared to SCM (Figures 2 and 3B).
These analyses also identified severalother genes previously shown to play a role in RMS pathogen-
esis, including Igf2, Dlk1, Ankrd1, Chrng, and Ncam1 (El-Badry
et al., 1990; Gattenloehner et al., 1998; Glu¨er et al., 1998; Ishi-
guro et al., 2008; Rezvani et al., 2012). Real-time PCR validation
of the array is shown in Figure S2A.
During muscle development, a subset of myogenic pro-
genitors forgoes terminal differentiation and instead become
mononuclear satellite cells associated with the myofiber basal
lamina. Muscle satellite cells are responsible for the postnatal
growth, repair, and maintenance of skeletal muscle (Seale and
Rudnicki, 2000). Satellite cells remain quiescent until activated
by muscle injury, when they serve as muscle-specific stem cells
that generate myogenic precursors and repair injured muscle
(Shadrach and Wagers, 2011). Mice with loss-of-function of
p53 and gain-of-function of the Shh pathway through the loss
of Ptch1 in myoblasts and satellite cell lineages develop tumors
that resemble human ERMS and display a gene expression
signature consistent with satellite cell activation (Rubin et al.,
2011). Interestingly, the tumors arising from the adipocyte-
specific aP2-Cre driver expressed numerous genes associated
with satellite cell activation (Fukada et al., 2007), including Rho
GDP dissociation inhibitor gamma (Arhgdig), ankyrin repeatOctober 16, 2012 ª2012 Elsevier Inc. 539
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Figure 4. Cdkn2a Loss Cooperates in aP2-Cre;SmoM2 Mouse
Tumors
Kaplan-Meier survival curves illustrate tumor-free survival of aP2-Cre;
SmoM2/+;Cdkn2aFloxmice (green line, n = 27) compared to data from Figure 1C
aP2-Cre;SmoM2/+ (blue line, n = 47) and SmoM2/+ littermate controls (red line,
n = 19). p = 0.0337.
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Adipocyte Origin of Rhabdomyosarcomadomain 1 (Ankrd1), (fetal) nicotinic cholinergic receptor gamma
polypeptide (Chrng), distal-less homeobox 2 (Dlx2), hairy and
enhancer of split (Hes6), low density lipoprotein receptor-related
protein 4 (Lrp4), Otogelin (Otog), Secretin (Sct), troponin C
(Tnnc1), troponin T1 (Tnnt1), cardiac troponin T2 (Tnnt2), and
unc-5 homolog B (Unc5b) (Figure S2B). Twenty percent of all
the genes with increased expression of 5-fold or greater in the
aP2-Cre;SmoM2/+ tumors display increased expression in acti-
vated satellite cells compared to quiescent satellite cells. Thus,
despite arising from the aP2 adipocyte lineage, the aP2-Cre;
SmoM2/+ tumors displayed a gene expression profile similar to
other murine ERMS models and activated satellite cells. These
findings suggest that the satellite cell gene expression signature
is likely reflective of the ERMS tumor pathology rather than the
cell type of origin of the tumor.
To further test how the aP2-Cre;SmoM2/+ tumors resemble
previously reported mouse ERMS models, we compared the
gene expression pattern of our model to that of previously
published mouse ERMS. The comparison group contained
mouse tumors that developed from the conditional deletion of
Ptch1flox/+ and Trp53flox/flox alleles with Myf5-Cre, Pax3-Cre,
and Pax7-CreERp, respectively (Rubin et al., 2011). Overall,
67% of the 19,878 probe pairs showed agreement in gene
expression between our model and the previously published
models (Figure 3D). Next, we used cross-species comparison
of the mouse and human ERMS transcriptomes to determine
how closely the aP2-Cre;SmoM2/+ tumors resemble human
ERMS. We observed a statistically significant match between
the mouse aP2-Cre;SmoM2/+ tumors and human ERMS (Fig-
ure 3E). Of the 13,282 ortholog gene pairs, 58% showed
agreement in gene expression between mouse and human.
Together, these data confirm that the aP2-Cre;SmoM2/+ mouse
tumors accurately model the transcriptome of both previously
published mouse models and human ERMS.
Cooperativity between SmoM2 Activation
and Cdkn2a Loss
The tumor suppressor CDKN2A is one of the most commonly
mutated alleles in human cancer (Beroukhim et al., 2010; Bignell
et al., 2010). Homozygous deletions of CDKN2A have been
reported in ERMS (Chen et al., 2007; Iolascon et al., 1996; Paul-540 Cancer Cell 22, 536–546, October 16, 2012 ª2012 Elsevier Inc.son et al., 2011; Williamson et al., 2010). To test for potential
cooperativity between Cdkn2a and hedgehog-driven ERMS,
we intercrossed a conditional Cdkn2aFlox allele into our model
(Aguirre et al., 2003). aP2-Cre;Cdkn2aFlox/Flox mice did not
develop ERMS, whereas deletion of Cdkn2a in aP2-Cre;
SmoM2/+;Cdkn2aFlox/Flox mice triggered decreased latency and
increased penetrance of tumorigenesis with all mice having
tumors by 55 days (Figure 4). These results demonstrate that
the Shh pathway and Cdkn2a can actively drive ERMS oncoge-
nicity in vivo.
Sonic Hedgehog Activation in the Embryonic Muscle
Lineage and Postnatal Satellite Cells
We next crossed the SmoM2 allele to mice bearing several
muscle lineage-restricted Cre-drivers to determine whether acti-
vation of the Shh pathway by expression of the SmoM2 oncogene
in the muscle lineage would phenocopy the tumors of the aP2-
Cre;SmoM2/+mice. Activation of the SmoM2 allele early in muscle
development with Myf5-Cre, Pax3-Cre, or MyoD1-Cre resulted
in embryonic lethality without tumor formation, whereas mice
with activation of SmoM2 in terminally differentiated skeletal
muscle with MCK-Cre were viable with no evidence of tumori-
genesis (Figure S3).
In contrast, activation of SmoM2 with Myogenin-Cre, which is
specific for early muscle differentiation, resulted in tongue
tumors in 100% of the mice (Figure 5A) but no tumors in the
anterior neck, as seen in aP2-Cre;SmoM2/+ mice. Specifically,
the Myogenin-Cre;SmoM2/+ mice were runted compared to
littermates and were sacrificed between 19 and 39 days for
lack of weight gain and ill appearance. None of the Myogenin-
Cre;SmoM2/+mice had visible tumors prior to sacrifice; however,
all Myogenin-Cre;SmoM2/+ mice had tumors visible upon
necropsy throughout the tongue (Figure 5B). The Myogenin-
Cre;SmoM2/+ tumors appeared histologically similar to the
aP2-Cre;SmoM2/+ tumors and stained positive both MyoD1
and Myogenin. We detected no significant difference in the
gene expression profile of the Myogenin-Cre;SmoM2/+ tumors
and the aP2-Cre;SmoM2/+ (Figures 5C and 5D). The embryonic
lethality of SmoM2 expression early in muscle development
withMyf5-Cre, Pax3-Cre, andMyoD1-Cre and the more aggres-
sive phenotype with the Myogenin-Cre suggests that aP2-Cre
does not globally activate SmoM2 expression in the muscle
lineage.
Previous studies illustrate that satellite cells are a potential
origin for ERMS (Hettmer et al., 2011; Rubin et al., 2011; Tiffin
et al., 2003). Given the activated satellite cell signature of the
aP2-Cre;SmoM2/+ tumors, we sought to formally test whether
satellite cells are an origin of the aP2-Cre;SmoM2/+ tumors.
The Pax7-CreERT2 allele allows for specific SmoM2 postnatal
induction in both quiescent and activated satellite cells (Lepper
et al., 2009). We crossed the SmoM2 mouse with the satellite
cell Cre-driver, Pax7-CreERT2 and administered tamoxifen at
day-of-life 1 or day-of-life 14 (Figure S3G). Gene expression
from the SCM containing only a small fraction of satellite cells
from the Pax7-CreERT2;SmoM2/+ and SmoM2/+ Cre-negative
littermates revealed that the SmoM2 (that has a carboxy terminal
YFP fusion) was activated following tamoxifen administration
(Figure S3H). None of the Pax7-CreERT2;SmoM2/+ animals in-
jected with tamoxifen at either day 1 (n = 8) or day 14 (n = 9)
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Figure 5. Tongue ERMS in Myogenin-Cre;
SmoM2 Mice
(A) Kaplan-Meier survival curves illustrated tumor-
free survival of Myogenin-Cre;SmoM2/+ mice
(green line, n = 12) and of MCK-Cre;SmoM2/+ (red
line, n = 18) compared to tumor-free survival of
aP2-Cre;SmoM2/+ from Figure 1C (blue line).
(B) Tumor histology. (a) Gross cross-section of
tongue with tumor outlined by white, dashed
line. (b) H&E section illustrating cross striations.
(c and d) Immunochemistry illustrating nuclear
MyoD1 and Myogenin. Scale bars, 2 mm (a) and
50 mm (b, c, and d).
(C) Principle component analysis for mouse
Myogenin-Cre;SmoM2/+ tumors (green, n = 3) and
aP2-Cre;SmoM2/+ tumors (red, n = 12).
(D) Volcano plot of the Log10 of the p value versus
the Log2 of the fold-difference in expression in
the aP2-Cre;SmoM2/+ tumors compared to the
Myogenin-Cre;SmoM2/+ tumors.
See also Figure S3.
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Adipocyte Origin of Rhabdomyosarcomadeveloped tumors by 150 days, arguing against the satellite cell
population as the origin of the ERMS in the aP2-Cre;SmoM2/+
model.
aP2-Cre Is Active in Adipose Tissue but Not Skeletal
Muscle
The development of tumors that resemble human ERMS from
activation of the oncogenic SmoM2 allele in the aP2 adipocyte
lineage was surprising. However, despite arising from the aP2
lineage, the aP2-Cre;SmoM2/+ tumors did not express aP2 or
other genes of the adipocyte lineage (Figure S4A). Consistent
with previous reports, we determined that aP2 is expressed
in the progenitors from the stromal vascular fraction of brown
adipose tissue (BAT) and white adipose tissue (WAT), as well
as mature adipocytes. However, aP2 was not expressed from
satellite cells or the SCM, gastrocnemius, or quadriceps femo-
ris skeletal muscles (Figure S4B). The aP2-Cre transgenic used
in this study was previously characterized and reported not to
be expressed in the muscle lineage (Tang et al., 2008). More-
over, the identical 5.4 kb aP2 promoter element was previously
shown to be adipose-specific and to result in hibernoma forma-
tion, not ERMS, when fused to simian virus 40 Large T antigen
(He et al., 2003; Ross et al., 1990, 1992). Another aP2-Cre
transgene containing the same 5.4 kb aP2 promoter has also
been shown to be inactive in the muscle lineage but to be
active primarily in BAT and WAT and in the developing carti-
lage, vertebra, and dorsal root ganglia (He et al., 2003; Urs
et al., 2006).
To confirm the pattern of expression of aP2-Cre and to further
define the origins of tumors in the aP2-Cre;SmoM2/+ mice, we
again turned to aP2-Cre;R26-LacZ reporter mice. The aP2-
Cre was activated in both BAT and WAT but showed no detect-
able expression in skeletal muscle (Figure 6A), suggesting that
RMS in these mice arises from a nonskeletal muscle origin.
We compared the gene expression in isolated intrascapularCBAT, inguinal WAT, SCM, and gastrocnemius skeletal muscle,
and tumor from the aP2-Cre;SmoM2/+ and SmoM2/+ Cre-nega-
tive littermates. Although the oncogenic SmoM2 allele was acti-
vated in the fat lineage, the tumors did not express adipocyte
lineage genes, such as aP2, Pparg, and Ucp1 (Figures S4C–
S4E). Also, the normal skeletal muscle from the aP2-Cre;
SmoM2/+ mice did not display increased Smo and Shh target
genes, suggesting that SmoM2 was not activated in the muscle
lineage.
To further test whether the aP2-Cre transgene is inactive in
skeletal muscle, we bred aP2-Cremice to an additional reporter
allele, R26-YFP. A western blot for YFP of whole tissue lysates of
isolated intrascapular BAT, inguinal WAT, and SCM from aP2-
Cre;R26-YFP and R26-YFP littermates at P28 demonstrated no
evidence of YFP expression in skeletal muscle (Figures S4F
and S4G). Together, these data illustrate that the aP2-Cre
transgene is not expressed in skeletal muscle, consistent with
the notion that the aP2-Cre;SmoM2/+ ERMS tumors originate
outside the skeletal muscle lineage.
ERMS in Adipose Tissue
To better delineate the tissue compartment giving rise to the
aP2-Cre;SmoM2 ERMS tumors, we sacrificed animals at P14,
before tumor masses were grossly visible, with the notion of
capturing microscopic foci of RMS arising in situ. The
dissected SCM of a representative animal contained a small
nodule clearly distinct from adjacent normal brown and white
adipose tissues and SCM skeletal muscle (Figure 6B). The
developing tumor was completely surrounded by nonneoplastic
adipose tissue adjacent to and clearly separated from the SCM.
The tumor displays the same appearance and histological
characteristics as the previously described aP2-Cre;SmoM2/+
tumors. These findings further support the notion that the
ERMS in the aP2-Cre;SmoM2/+ mice develop outside of the
muscle lineage.ancer Cell 22, 536–546, October 16, 2012 ª2012 Elsevier Inc. 541
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Lineages and aP2-Cre;SmoM2 Tumors in
Adipose Tissue Adjacent to Muscle
(A) Mice bearing Cre-drivers aP2-Cre, Myf5-Cre,
and Myogenin-Cre were bred to R26-LacZ
reporter mice. The BAT, WAT, gastrocnemius, and
SCMwere isolated fromP28mice and stainedwith
X-gal to determine b-galactosidase activity. Scale
bars, 5 mm.
(B) Serial sections through neck tissue with
a visible node at P14 on necropsy and stained with
H&E. (Left) Level below nodule illustrating normal
SCM and adjacent adipose tissue. Arrow and
arrowhead point to SCM and adipose tissue,
respectively. Scale bar, 200 mm. (Middle) Section
illustrating the tumor isolated within the adipose
tissue. The open arrowhead points to tumor.
Scale bar, 200 mm. (Right) High power view of
tumor. Scale bar, 20 mm.
See also Figure S4.
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Through adipocyte-restricted activation of the hedgehog
pathway, we have developed a highly efficient mouse model of
ERMS. Our findings demonstrate that constitutive activation of
the hedgehog pathway by an oncogenic Smoothened allele in
the aP2 adipocyte lineage of mice results in the formation of
aggressive head and neck tumors that mimic human ERMS
histologically and molecularly. Though we cannot completely
exclude the unlikely possibility that aP2-Cre is expressed in
a rare population of myogenic cells, together these findings
strongly argue that ERMS driven by the Shh pathway can origi-
nate from tissue histologically distinct from muscle.
Although activation of the Shh pathway inhibits fat forma-
tion in invertebrates and mammalian cellular models acting
upstream of PPARg (Suh et al., 2006), the Shh pathway has
well documented roles in skeletal muscle development and
in the pathogenesis of ERMS (Barlow et al., 1997; Fan and
Tessier-Lavigne, 1994; Johnson et al., 1994; Mu¨nsterberg
et al., 1995; Zibat et al., 2010). The role of the Shh pathway in
the development of ERMS is also supported by human cancer
predisposition syndromes that result in Shh pathway activation
and recent genomic interrogation of human ERMS samples.
Gorlin syndrome, or nevoid basal cell carcinoma syndrome, is
a human genetic disorder resulting from germline inactivating542 Cancer Cell 22, 536–546, October 16, 2012 ª2012 Elsevier Inc.mutations of PTCH1, which encodes
a negative regulator of the Shh pathway
and displays an increased incidence of
ERMS. Increased expression of GLI1
and PTCH1 in ERMS compared to
ARMS has been reported (Paulson et al.,
2011; Pressey et al., 2011). Zibat et al.
(2010) found that high levels of expres-
sion of Shh target genes, PTCH1, GLI1,
GLI3, and MYF5 are a common feature
of ERMS and fusion gene-negative
ARMS and not of fusion gene-positive
ARMS. High expression of PTCH1 alsocorrelated with poor survival (Zibat et al., 2010). These find-
ings illustrate that the hedgehog pathway influences RMS
pathogenesis.
The tumor-free survival curve of the aP2-Cre;SmoM2/+ mice
displays a biphasic appearance with some mice never devel-
oping tumors. The early development of tumors with approxi-
mately 50% of mice exhibiting tumors by 28 days of life shows
that activation of SmoM2 is sufficient to initiate ERMS tumori-
genesis. However, the incomplete penetrance of the model
suggests that other genetic ‘‘hits’’ are likely necessary for
complete neoplastic transformation and/or tumor progression.
For example, the tumor suppressor CDKN2A encoding
p16INK4A and p14ARF (p19Arf in mice) is commonly deleted in
human ERMS, which causes concomitant deregulation of the
Rb and p53 pathways (Chen et al., 2007; Iolascon et al., 1996;
Paulson et al., 2011). Deletion of Cdkn2a was previously shown
to cooperate with a c-Met-driven ERMS mouse model (Sharp
et al., 2002). The deletion of Cdkn2a in the aP2-Cre;SmoM2/+
model resulted in complete penetrance, illustrating cooperativity
between the Shh pathway and Ink4a/Arf in RMS.
Through mouse crosses deleting Ptch1 and p53 with multiple
muscle-specific Cre drivers, Rubin et al. (2011) recently demon-
strated that ERMS developed upon inactivating these loci in
muscle stem cells (satellite cells), as well as proliferating and
maturing myoblasts. All ERMS tumors exhibited the same gene
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that the gene expression profile was more reflective of the final
state of the tumor rather than the lineage from which it arose
(Rubin et al., 2011). Though the aP2-Cre transgene is not active
in the muscle lineage, the gene expression profile of the ERMS
from aP2-Cre;SmoM2/+ mice is remarkably similar to previous
murine ERMS models and to that of human ERMS. Thus, in
multiple and seemingly unrelated settings, activated satellite
gene signatures are seen in both mouse and human ERMS.
To address whether satellite cells were the origin of the
aP2-Cre;SmoM2/+ tumors, we utilized the Pax7-CreERT2 allele.
Pax7 along with Pax3 play a critical role in the developing
skeletal muscle, where both Pax7- and Pax3-positive cells in
the dermomyotome give rise to the embryonic and fetal
myoblasts that form the primary and secondary muscle fibers.
Consistent with these observations, we show that using Pax3-
Cre to activate the SmoM2 allele during development causes
embryonic lethality. Also, using Cre-drivers (Myf5-Cre and
MyoD1-Cre) that act downstream of Pax7 during myogenesis
also caused embryonic lethality. Thus, in lieu of using the
Pax7-CreERT2 allele to induce SmoM2 expression embryonically,
which would globally disrupt muscle patterning and cause
potent embryonic lethality, we focused on tamoxifen-induced
activation of the Pax7-CreERT2;SmoM2/+ alleles in newly born
pups, a time point at which Pax7 becomes restricted to the
satellite cell lineage. Indeed, lethality was circumvented by
this approach, which allowed for viable animals to be profiled
for tumorigenesis. This dedicated restricted activation of the
oncogenic SmoM2 allele in the Pax7+ satellite cells did not result
in tumor formation. If aP2-Cre was expressed at a level that was
completely undetectable in either of the lineage tracing experi-
ments with the R26-LacZ or R26-YFP mice in the satellite
cells, and the satellite cells were the origin of these tumors,
one would expect that oncogene activation in the satellite cell
lineage would phenocopy the aP2-Cre;SmoM2/+ tumors, which
was not observed.
The cell of origin of ERMS has been and continues to be
ambiguous (Hettmer and Wagers, 2010). It is generally thought
that ERMS develops from cells of the muscle lineage, given
that ERMS express skeletal muscle markers, such as MyoD,
Myogenin, and Desmin. However, an origin restricted to muscle
progenitors does not explain how ERMS occurs in locations
that lack striated muscle, such as the prostate, urinary bladder,
and the biliary tree (Heyn et al., 1997; Spunt et al., 2000). Trans-
differentiation of mesenchymal progenitor cells, including
progenitors of the adipose lineage into ERMS, could account
for ERMS that arise in tissues that normally lack skeletal muscle,
such as the biliary and genitourinary tract. Transdifferentiation
of lineages not fated to become skeletal muscle could also
explain the appearance of arrested skeletal muscle develop-
ment, as lineages that transdifferentiate after their fate has
been initially established could lack the developmental priming
necessary to terminally differentiate into striated skeletal muscle.
Recent reports suggest that skeletal muscle and brown fat
share a developmental ancestry (Atit et al., 2006; Kajimura
et al., 2009; Seale et al., 2008). In humans, brown fat has
traditionally been thought to be restricted to newborns.
However, recent reports have shown that brown adipose tissue,
located primarily in the supraclavicular neck, is readily activatedCupon cold exposure in adult humans (Cypess et al., 2009; van
Marken Lichtenbelt et al., 2009; Virtanen et al., 2009). We spec-
ulate that constitutive activation of the Shh pathway by SmoM2
derails brown adipocyte progenitors into the muscle lineage,
such that the resulting cells lack the previous developmental
priming and necessary modifications to develop normally into
mature skeletal muscle and thus display an arrested state of
skeletal muscle development or ERMS.
The rhabdomyosarcoma tumors in aP2-Cre;SmoM2/+ mutant
mice closely resemble human rhabdomyosarcoma with respect
to location, histology, and gene expression. We postulate that
the relatively short latency and high penetrance of ERMS in
this model now provides an efficient genetic system and tool
for the analysis of RMSmodifiers and provides a unique platform
for preclinical studies.
EXPERIMENTAL PROCEDURES
Mouse Strains
All mice used in this study have been previously reported: aP2-Cre (Tang et al.,
2008),SmoM2 (Jackson Laboratories, Bar Harbor, ME, USA; #5130) (Mao et al.,
2006), Cdkn2aFlox (Aguirre et al., 2003), Pax3-Cre (Jackson Laboratories,
#5549) (Engleka et al., 2005), Myf5-Cre (Jackson Laboratories, #7893)
(Tallquist et al., 2000),MyoD1-Cre (Jackson Laboratories, #14140) (Yamamoto
et al., 2009), Myogenin-Cre (Li et al., 2005), MCK-Cre (Jackson Laboratories,
#6475) (Bru¨ning et al., 1998), Pax7-CreERT2 (Jackson Laboratories, #12476)
(Lepper et al., 2009) R26-LacZ (Jackson Laboratories, #3474) (Soriano,
1999), and R26-YFP (Jackson Laboratories, #6148) (Srinivas et al., 2001).
aP2-Cre;SmoM2/+ mice were generated by breeding aP2-Cre male animals
to SmoM2/M2 females. aP2-Cre;SmoM2/+;Cdkn2aFl/Fl mice were generated
by breeding aP2-Cre;Cdkn2aFl/Fl males with SmoM2/M2;Cdkn2aFl/Fl females.
All mice used in these studies were of mixed genetic backgrounds, and all
comparisons were performed on littermate controls. The end point for the
Kaplan-Meier tumor-free survival analysis was the first visible sign of tumor.
All experimental procedures involving animals in this study were reviewed
and approved by the Institutional Animal Care and Research Advisory
Committee at the University of Texas Southwestern Medical Center.
Histology and Immunohistochemistry
Dissected tumors were fixed in 10% neutral-buffered formalin, placed in
fixative overnight, embedded in paraffin, and sectioned at 5 mm intervals.
Hematoxylin and eosin (H&E) and Trichrome stains were performed using
standard procedures. All paraffin-embedded sections for immunohistochem-
istry were deparaffinized, heated in a microwave in 0.01 M sodium citrate
buffer for antigen retrieval, treated with 3% H2O2 for 10 min, and rinsed in
H2O and PBS. For Ki-67 immunohistochemistry, sections were blocked in
5% goat serum in PBS, followed by incubation with anti-Ki67 antibody
(Abcam, Cambridge, UK; ab15580) at a concentration of 1:100. Signals were
detected with a Vectastain ABC kit (Vector Laboratories, Burlingame, CA,
USA) and 3,30-diaminobenzidine (DAB) substrate (Vector Laboratories).
Sections were counterstained with hematoxylin and mounted. For MyoD,
Myogenin, and Desmin immunohistochemistry, the M.O.M. Immunodetec-
tion Kit (Vector Laboratories), Vectastain Elite kit (Vector Laboratories), and
3,30-diaminobenzidine (DAB) substrate were used. The MyoD1 primary anti-
body (Dako, Carpinteria, CA, USA; 5.8A, M3512) was used at a concentration
of 1:50, the Myogenin primary antibody (Dako, 5FD, M3559) was used at
a concentration of 1:25, and the Desmin primary antibody (Developmental
Hybridoma Bank, D3 supernatants) was used at a concentration of 1:100.
LacZ Staining
b-galactosidase expression was detected in isolated tissue fixed for 1 hr in
4% paraformaldehyde, 0.1 M phosphate buffer (pH 7.4), 0.01% sodium
deoxycholate, and 0.02% Nonidet P-40 and then washed twice with buffer
(0.1 M phosphate buffer [pH 7.4], 0.01% sodium deoxycholate, and 0.02%
Nonidet P-40). b-galactosidase was detected by overnight incubation atancer Cell 22, 536–546, October 16, 2012 ª2012 Elsevier Inc. 543
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side), 5 mM potassium ferricyanide, and 5 mM potassium ferrocyanide, 2 mM
MgCl2, 0.01% sodium deoxycholate, and 0.02% Nonidet P-40. Tissues were
rinsed twice in buffer and postfixed overnight in 4% paraformaldehyde and
0.2% glutaraldehyde.
RNA Purification, RT-PCR, and Real-Time PCR
Total RNA was isolated from normal SCM or tumors with Trizol reagent
(Invitrogen, Carlsbad, CA, USA) in accordance with the manufacturer’s
protocol. Reverse transcription was performed using random hexamer
primers and SuperScript III First-Strand Synthesis (Invitrogen). Real-time
PCR was performed using SYBR Green assay on an ABI-PE Prism 7900HT
sequence detection system in accordance with manufacturer’s protocol.
The relative quantities of the gene of interest were determined using the
DDCT method and were normalized to 18S and expressed relative to the value
for the normal SCM or to brown adipose tissue. In all real-time PCR assays,
each group contained four independent samples assayed in duplicate.
Microarray Analysis
RNA from aP2-Cre;SmoM2/+ tumors or SCMwith quality verifiedwith nanodrop
and bioanalyzer was hybridized to the Illumina MouseWG-6 v2.0 BeadChip.
Normalized signal data from Illumina Whole-Genome Gene Expression
BeadChips were collated and log base 2 transformed in STATA/SE 11.2
(College Station, TX, USA). Next, the data was imported into Partek Genomic
Suite 6.6 (St. Louis, MO, USA) visualized by principal components analysis
(PCA) to check for consistency of samples and class variance. The log2
transformed aP2-Cre;SmoM2/+ tumor and SCM data were batch corrected
and then compared. Using Partek, each probeset was compared by an
unequal variance t test. The Bonferroni correction was then applied. This
same process was repeated for aP2-Cre;SmoM2/+ and Myogenin-Cre;
SmoM2/+ data.
Probesets that passed the Bonferroni cutoff at 0.0001 in the aP2-Cre;
SmoM2/+ tumor, SCM comparison, and had an absolute value of the log2ratio
>2.5 were selected for the heat map. Using Spotfire Decision Site 9.1.2,
the data were z transformed and hierarchically clustered using Euclidean
distance; data was then recolored to the fixed 2 to 2 scale. The volcano
plot was produced in STATA/SE 11.2 by first log10 transforming the p value
from the unequal variance t test. The transformed score was then plotted
against the log2ratio of expression from the two classes. The horizontal line
represents the 0.05 Bonferroni cutoff, and the colors represent select signifi-
cantly differential genes that are either elevated (red) in aP2-Cre;SmoM2/+
tumor relative to SCM or downregulated (green). The volcano plot for the
aP2-Cre;SmoM2/+/Myogenini-Cre;SmoM2/+ t test results was created in the
same manner. Although in this case, no genes had statistically significant
differences. Gene expression was confirmed by real-time PCR.
Cross-Species and Mouse Model Expression Comparisons
The human data comes from two distinct studies: the 36 ERMS samples from
the Curie Institute (Williamson et al., 2010) and Vastus Lateralis muscle of ten
young trained subjects from the Mayo clinic (GSE9103). Both human studies
used the Affymetrix Human Genome U133 Plus 2.0 Arrays. Data was rma
summarized for each group independently (Partek Genomics Suite 6.6).
Next, ERMS/wt-muscle log ratios were calculated and median normalized to
center at zero to correct for source effects. The 15mouse tumors and 3 normal
SCM samples from this study were assayed by Illumina MouseWG-6 v2.0
BeadChip. Log2ratios were calculated, and the cross-species cross-platform
data were matched by unigene ID based on an Affymetrix cross-species
unigene file derived from NCBI homologene data. Whenever multiple probes
were designated for a given unigene in either species, the probe with the
maximum average expression was retained yielding 13,282 logratio pairs.
The Spearman Correlation, AGDEX (Johnson et al., 2010), and linear fit were
calculated and graphically depicted using STATA/SE 11.
The mouse model comparison was within species, but the cross two
version comparison above was used. The San Antonio model was performed
on the Illumina mouseRef-8 v1.1 expression beadchip. For the with intraspe-
cies comparison, four normal skeletal muscle samples and seven ERMS
samples from San Antonio were compared to our model data. Probe
matching was direct by Illumina ID yielding 19,878 pairs. AGDEX, Spearman544 Cancer Cell 22, 536–546, October 16, 2012 ª2012 Elsevier Inc.correlation, and linear fit were calculated and graphed as in the cross-
species example.
Statistical Analysis
Results are expressed as the mean ± SEM. We utilized a two-tailed, unpaired
Student’s t test for all pairwise comparisons (GraphPad Prism version 5).
p values less than 0.05 were considered significant.
ACCESSION NUMBERS
Illumina data for the mouse ERMS and SCM can be found in the Gene Expres-
sion Omnibus database under number GSE40359.
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